Literature DB >> 16687949

Angiotensin receptor blockers: new considerations in their mechanism of action.

Domenic A Sica1.   

Abstract

Angiotensin receptor blockers are one of several drug classes that act by hindering activity of the renin-angiotensin axis. Angiotensin receptor blockers act by selectively blocking the binding of angiotensin II to the angiotensin type 1 receptor but not the angiotensin type 2 receptor. Compounds in this class are as effective as most other antihypertensive drug classes in reducing blood pressure in the patient with hypertension. The mechanism of action of an angiotensin receptor blocker, which seemed a straightforward proposition early on, has of late become more convoluted with a host of class and compound-specific concerns having emerged. As the mechanistic basis for the action(s) of angiotensin receptor blockers more completely unfolds, added credence may ultimately be lent to widely touted and often overstated intraclass differences.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16687949      PMCID: PMC8109530          DOI: 10.1111/j.1524-6175.2005.05141.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  30 in total

Review 1.  Practical considerations of the pharmacology of angiotensin receptor blockers.

Authors:  M M McConnaughey; J S McConnaughey; A J Ingenito
Journal:  J Clin Pharmacol       Date:  1999-06       Impact factor: 3.126

Review 2.  Angiotensin AT2 receptors: cardiovascular hope or hype?

Authors:  Robert E Widdop; Emma S Jones; Ruth E Hannan; Tracey A Gaspari
Journal:  Br J Pharmacol       Date:  2003-10-06       Impact factor: 8.739

Review 3.  Clinical pharmacokinetics of candesartan.

Authors:  Christoph H Gleiter; Klaus E Mörike
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Treatment of non-dipper hypertension with bedtime administration of valsartan.

Authors:  Ramón C Hermida; Carlos Calvo; Diana E Ayala; José R Fernández; Manuel Covelo; Artemio Mojón; José E López
Journal:  J Hypertens       Date:  2005-10       Impact factor: 4.844

5.  Effect of angiotensin II receptor blockade on autonomic nervous system function in patients with essential hypertension.

Authors:  Henry Krum; Elisabeth Lambert; Emma Windebank; Duncan J Campbell; Murray Esler
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-11-11       Impact factor: 4.733

6.  Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade.

Authors:  E H Ohlstein; D P Brooks; G Z Feuerstein; R R Ruffolo
Journal:  Pharmacology       Date:  1997-11       Impact factor: 2.547

7.  [Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals].

Authors:  Burkhard Weisser; Martin Gerwe; Michael Braun; Christiane Funken
Journal:  Arzneimittelforschung       Date:  2005

Review 8.  A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker.

Authors:  David E Mire; Tonous N Silfani; Michael K Pugsley
Journal:  J Cardiovasc Pharmacol       Date:  2005-11       Impact factor: 3.105

9.  Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients.

Authors:  M R Goldberg; T E Bradstreet; E J McWilliams; W K Tanaka; S Lipert; T D Bjornsson; S A Waldman; B Osborne; L Pivadori; G Lewis
Journal:  Hypertension       Date:  1995-01       Impact factor: 10.190

Review 10.  Pharmacotherapy review: Angiotensin receptor antagonists.

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-11       Impact factor: 3.738

View more
  1 in total

1.  Beneficial effects of angiotensin II type 1 receptor blocker antihypertensive treatment on inflammation indices: the effect of smoking.

Authors:  Stella-Maria G Kyvelou; Gregory P Vyssoulis; Eva A Karpanou; Dionysios N Adamopoulos; Theodoros P Gialernios; Panagiota G Pietri; Dennis V Cokkinos; Christodoulos I Stefanadis
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-01       Impact factor: 3.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.